Lenvatinib (E7080) is a multi-target inhibitor. In cell-free tests, Lenvatinib is the most effective against VEGFR2(KDR)/VEGFR3(Flt-4), and IC50 is 4 nM/5.2 nM, which is slightly less effective against VEGFR1/Flt-1. The selectivity of PDGFRα/β for VEGFR2/3 is about 10 times higher than that for FGFR1. Lenvatinib (E7080) is also an inhibitor of FGFR1-4, PDGFR, Kit (c-Kit), and RET (c-RET), and has potent antitumor activity. Phase 3.

 

Brand: BCM

 

Targets: VEGFR2:4 nM (IC50); VEGFR3:5.2 nM (IC50)

 

Melting Point: >216°C (dec.)

 

Boiling Point: 627.2±55.0 °C at 760 mmHg

 

Flashing Point: 333.1±31.5 °C

 

Solubility: Soluble in DMSO. Insoluble in Water; insoluble in Ethanol.

 

Attribute
[Chem Name]	4-(3-Chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
[Synonym]	Lenvatinib; E7080
[CAS No.]	417716-92-8
[EINECS]	1592732-453-0
[MDL No.]	MFCD16038644
[Formula]	C21H19ClN4O4
[Molecular]	426.85
[Form]	White solid
[Storage]	-20°C

Goods Tag